AG
KYNB

Aperio Group’s Kyntra Bio KYNB Stock Holding History

Aperio Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$488K Buy
526
+21
+4% +$22.1K ﹤0.01% 1978
2020
Q3 		$520K Buy
505
+128
+34% +$138K ﹤0.01% 1790
2020
Q2 		$382K Buy
377
+9
+2% +$8.36K ﹤0.01% 1901
2020
Q1 		$319K Sell
368
-87
-19% -$86.5K ﹤0.01% 1870
2019
Q4 		$488K Sell
455
-41
-8% -$41.9K ﹤0.01% 1811
2019
Q3 		$459K Buy
496
+31
+7% +$34K ﹤0.01% 1801
2019
Q2 		$525K Sell
465
-117
-20% -$128K ﹤0.01% 1763
2019
Q1 		$791K Buy
582
+123
+27% +$167K ﹤0.01% 1486
2018
Q4 		$531K Buy
459
+114
+33% +$128K ﹤0.01% 1641
2018
Q3 		$523K Buy
345
+65
+23% +$100K ﹤0.01% 1739
2018
Q2 		$438K Buy
280
+101
+56% +$132K ﹤0.01% 1804
2018
Q1 		$207K Buy
+179
New +$236K ﹤0.01% 2127

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Aperio Group's KYNB Position: Q4 2020 in Review

Aperio Group increased its Kyntra Bio (KYNB) stake by 4.2% in Q4 2020, buying an estimated $22.1K and bringing the position to 526 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #1978.

Aperio Group first reported a position in KYNB in Q1 2018 and has held it in 12 quarters since. The position peaked at $791K in Q1 2019. 207 funds tracked by Wall St. Rank hold KYNB as of Q4 2020.

  • Aperio Group held 526 shares of Kyntra Bio worth $488K as of Q4 2020.
  • Aperio Group bought 21 Kyntra Bio shares in Q4 2020, an estimated $22.1K.
  • Kyntra Bio made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1978 holding.
  • Aperio Group first reported a position in Kyntra Bio in Q1 2018 and has held it in 12 quarters since.
  • Aperio Group's Kyntra Bio position peaked at $791K in Q1 2019.
  • 207 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.